We are live on ! Find out more
BBP icon

Virtus Biotech ETF
BBP

14 hedge funds and large institutions have $3.89M invested in Virtus Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more funds holding

Funds holding: 11 → 14 (+3)

22% more capital inflows, than outflows

Capital inflows: $1.8M | Capital outflows: $1.47M

0.24% less ownership

Funds ownership: 24.77% → 24.53% (-0.24%)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$1.27M
2
Stifel Financial
Stifel Financial
Missouri
+$271K
3
LPL Financial
LPL Financial
California
+$217K
4
Morgan Stanley
Morgan Stanley
New York
+$25.8K
5
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC)
Nebraska
+$13.9K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.31M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$82.2K
3
Citadel Advisors
Citadel Advisors
Florida
-$43.9K
4
UBS Group
UBS Group
Switzerland
-$28.3K
5
Focused Wealth Management
Focused Wealth Management
New York
-$9.23K

BBP Hedge Fund Activity: Q3 2022 in Review

14 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q3 2022, worth a combined $3.89M — up 8.8% from $3.58M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BBP positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $1.27M. The largest seller was Royal Bank of Canada, cutting an estimated $1.31M.

  • 14 institutional investors held Virtus Biotech ETF (BBP) as of Q3 2022, up from 11 in Q2 2022.
  • Funds reported $3.89M of Virtus Biotech ETF stock for Q3 2022, up 8.8% quarter-over-quarter.
  • 4 funds opened new Virtus Biotech ETF positions in Q3 2022 and 0 closed out, a net change of +4 holders.
  • The largest Virtus Biotech ETF buyer in Q3 2022 was Rockefeller Capital Management, an estimated $1.27M added.
  • The largest Virtus Biotech ETF seller in Q3 2022 was Royal Bank of Canada, an estimated $1.31M sold.

Based on aggregated 13F filings for Q3 2022.